MARKET

RXRX

RXRX

Recursion Pharmaceuticals, Inc.
NASDAQ
3.740
-0.150
-3.86%
After Hours: 3.770 +0.03 +0.79% 19:59 09/25 EDT
OPEN
3.890
PREV CLOSE
3.890
HIGH
3.900
LOW
3.700
VOLUME
10.48M
TURNOVER
--
52 WEEK HIGH
7.18
52 WEEK LOW
2.770
MARKET CAP
2.00B
P/E (TTM)
-3.6024
1D
5D
1M
3M
1Y
5Y
1D
How Investors Are Reacting To Recursion Pharmaceuticals (RXRX) RNA Model Licensing Deal
Simply Wall St · 20h ago
Squeeze Watch: 10 Stocks With Over 33% Short Interest
Benzinga · 1d ago
Recursion Pharmaceuticals (RXRX) Shares Just Moved, So What Is Driving Attention Now?
Simply Wall St · 3d ago
Recursion Pharmaceuticals (RXRX) Stock Moves 2.02%: What You Should Know
NASDAQ · 3d ago
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Recursion Pharmaceuticals (RXRX) and Contineum Therapeutics, Inc. Class A (CTNM)
TipRanks · 5d ago
Recursion, Tempus Expand AI and RNA Collaboration Agreements
TipRanks · 5d ago
Tempus AI, Recursion extend data license agreement, enter new license agreement
TipRanks · 5d ago
Tempus AI Extends Recursion Data Deal Through 2029, Replacing Potential $84M Fees With $42M In Committed Payments, In Addition To Licensing Recursion’s RNA Foundation Model "TxFM" Under A Separate License Agreement
Benzinga · 5d ago
More
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.

Webull offers Recursion Pharmaceuticals Inc stock information, including NASDAQ: RXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RXRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RXRX stock methods without spending real money on the virtual paper trading platform.